Bicara Therapeutics (BCAX) Competitors $10.84 -0.73 (-6.31%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$10.90 +0.06 (+0.60%) As of 06/13/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX vs. APLS, XENE, AMRX, MIRM, ARWR, NAMS, RXRX, KNSA, VCEL, and GMTXShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors Apellis Pharmaceuticals Xenon Pharmaceuticals Amneal Pharmaceuticals Mirum Pharmaceuticals Arrowhead Pharmaceuticals NewAmsterdam Pharma Recursion Pharmaceuticals Kiniksa Pharmaceuticals Vericel Gemini Therapeutics Bicara Therapeutics (NASDAQ:BCAX) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation. Does the media favor BCAX or APLS? In the previous week, Apellis Pharmaceuticals had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 11 mentions for Apellis Pharmaceuticals and 10 mentions for Bicara Therapeutics. Apellis Pharmaceuticals' average media sentiment score of 1.34 beat Bicara Therapeutics' score of 0.74 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Apellis Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, BCAX or APLS? Bicara Therapeutics has higher earnings, but lower revenue than Apellis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/AN/AN/AN/AApellis Pharmaceuticals$775.84M3.05-$528.63M-$1.79-10.52 Do analysts recommend BCAX or APLS? Bicara Therapeutics currently has a consensus price target of $31.86, suggesting a potential upside of 193.90%. Apellis Pharmaceuticals has a consensus price target of $40.05, suggesting a potential upside of 112.71%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Bicara Therapeutics is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62 Does the MarketBeat Community favor BCAX or APLS? Apellis Pharmaceuticals received 336 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 72.73% of users gave Bicara Therapeutics an outperform vote while only 66.29% of users gave Apellis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBicara TherapeuticsOutperform Votes1672.73% Underperform Votes627.27% Apellis PharmaceuticalsOutperform Votes35266.29% Underperform Votes17933.71% Do institutionals & insiders have more ownership in BCAX or APLS? 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 15.5% of Bicara Therapeutics shares are owned by company insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is BCAX or APLS more profitable? Bicara Therapeutics has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -34.97%. Bicara Therapeutics' return on equity of 0.00% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Apellis Pharmaceuticals -34.97%-103.11%-28.96% SummaryBicara Therapeutics beats Apellis Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$630.98M$6.88B$5.57B$8.50BDividend YieldN/A2.48%5.27%4.17%P/E RatioN/A8.4626.7519.66Price / SalesN/A261.91403.98152.07Price / CashN/A65.8538.2534.64Price / BookN/A6.526.964.59Net IncomeN/A$143.26M$3.23B$248.23M7 Day Performance-5.74%-0.21%-1.22%-1.07%1 Month Performance-25.09%10.62%6.34%2.59%1 Year PerformanceN/A3.63%33.05%13.50% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics2.0544 of 5 stars$10.84-6.3%$31.86+193.9%N/A$630.98MN/A0.0032Analyst RevisionGap UpAPLSApellis Pharmaceuticals4.7584 of 5 stars$19.39+0.6%$40.05+106.6%-55.2%$2.44B$775.84M-9.55770Analyst RevisionGap UpXENEXenon Pharmaceuticals3.6567 of 5 stars$31.45-0.6%$54.82+74.3%-12.1%$2.41B$7.50M-11.15210Positive NewsOptions VolumeAnalyst RevisionAMRXAmneal Pharmaceuticals3.5293 of 5 stars$7.61-0.1%$11.60+52.4%+12.5%$2.39B$2.83B-11.197,600MIRMMirum Pharmaceuticals3.2189 of 5 stars$47.05+1.4%$60.73+29.1%+91.5%$2.33B$379.25M-23.29140Analyst RevisionARWRArrowhead Pharmaceuticals3.7013 of 5 stars$16.57-1.4%$43.71+163.8%-39.1%$2.29B$545.21M-3.21400Analyst UpgradeAnalyst RevisionNAMSNewAmsterdam Pharma2.9594 of 5 stars$20.16+0.1%$42.86+112.6%+5.3%$2.26B$47.14M-10.724Analyst ForecastAnalyst RevisionGap UpRXRXRecursion Pharmaceuticals1.9248 of 5 stars$5.37-2.2%$7.60+41.5%-46.9%$2.23B$59.82M-3.51400Analyst RevisionGap DownHigh Trading VolumeKNSAKiniksa Pharmaceuticals3.2302 of 5 stars$30.33+0.3%$38.80+27.9%+50.8%$2.21B$481.17M-216.63220Analyst UpgradeInsider TradeVCELVericel2.4629 of 5 stars$43.82+1.2%$61.14+39.5%+0.9%$2.21B$238.54M730.46300Positive NewsGap DownGMTXGemini TherapeuticsN/A$50.02+4.2%N/A+37.2%$2.17BN/A-50.0230News Coverage Related Companies and Tools Related Companies APLS Competitors XENE Competitors AMRX Competitors MIRM Competitors ARWR Competitors NAMS Competitors RXRX Competitors KNSA Competitors VCEL Competitors GMTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
